ENDPOINTS

Pharma companies are weighing how a drug’s IP location could impact tariffs

Over the past few months, several biopharma companies like GSK, Merck, Alnylam and BioMarin have said they are monitoring how the location of their drugs’ intellectual property could be relevant to President Donald Trump’s forthcoming ...

Jun 20, 2025 - 16:50
 0
Pharma companies are weighing how a drug’s IP location could impact tariffs
Over the past few months, several biopharma companies like GSK, Merck, Alnylam and BioMarin have said they are monitoring how the location of their drugs’ intellectual property could be relevant to President Donald Trump’s forthcoming ...
Read More

Tags:

Previous Article

High winds scrub Rocket Lab's planned launch of a secret satellite to orbit

Next Article

Nigerian communities to take Shell to high court over oil pollution

Related Posts

Bavarian Nordic's PRV goes for $160M; Biomea to advance GLP-1 into trials

Bavarian Nordic's PRV goes for $160M; Biomea to advance...

Jun 18, 2025  0

Another care navigation deal

Another care navigation deal

Jun 12, 2025  0

GLP-1s may cut cancer risk; Gyre’s stock falls after hepatitis C data and offering

GLP-1s may cut cancer risk; Gyre’s stock falls after he...

May 23, 2025  0